BIOCRYST PHARMACEUTICALS INC financial data

Symbol
BCRX on Nasdaq
Location
Durham, NC
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 04 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 238% % -24%
Quick Ratio 4% % -70%
Debt-to-equity -208% %
Return On Equity 2% % -92%
Return On Assets -2% % 93%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 210,543,224 shares 1.6%
Common Stock, Shares, Outstanding 210,522,000 shares 1.6%
Entity Public Float $1,264,650,517 USD -4.4%
Common Stock, Value, Issued $2,105,000 USD 1.6%
Weighted Average Number of Shares Outstanding, Basic 210,176,000 shares 1.6%
Weighted Average Number of Shares Outstanding, Diluted 219,885,000 shares 6.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $174,700,000 USD -11%
Costs and Expenses $523,720,000 USD 16%
Operating Income (Loss) $76,096,000 USD 285%
Nonoperating Income (Expense) $82,713,000 USD 17%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $6,617,000 USD 95%
Income Tax Expense (Benefit) $2,162,000 USD -231%
Net Income (Loss) Attributable to Parent $8,779,000 USD 93%
Earnings Per Share, Basic 0 USD/shares 92%
Earnings Per Share, Diluted 0 USD/shares 92%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $84,078,000 USD -13%
Accounts Receivable, after Allowance for Credit Loss, Current $91,325,000 USD 26%
Inventory, Net $5,232,000 USD -31%
Assets, Current $355,684,000 USD -17%
Property, Plant and Equipment, Net $8,396,000 USD 13%
Operating Lease, Right-of-Use Asset $7,725,000 USD -7.3%
Other Assets, Noncurrent $4,387,000 USD -72%
Assets $446,424,000 USD -9.1%
Accounts Payable, Current $5,567,000 USD -59%
Employee-related Liabilities, Current $48,631,000 USD 33%
Accrued Liabilities, Current $118,778,000 USD 14%
Liabilities, Current $190,237,000 USD 24%
Operating Lease, Liability, Noncurrent $8,425,000 USD 4.5%
Liabilities $834,313,000 USD -13%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,140,000 USD -50%
Retained Earnings (Accumulated Deficit) $1,752,024,000 USD -0.5%
Stockholders' Equity Attributable to Parent $387,889,000 USD 17%
Liabilities and Equity $446,424,000 USD -9.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $27,517,000 USD 49%
Net Cash Provided by (Used in) Financing Activities $529,000 USD
Net Cash Provided by (Used in) Investing Activities $27,095,000 USD -5.8%
Common Stock, Shares Authorized 450,000,000 shares 0%
Common Stock, Shares, Issued 210,522,000 shares 1.6%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $558,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $106,323,000 USD -5.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities $9,153,000 USD 84%
Deferred Tax Assets, Valuation Allowance $448,740,000 USD 2.7%
Deferred Tax Assets, Gross $453,183,000 USD 2.7%
Operating Lease, Liability $8,773,000 USD -3.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $9,932,000 USD 92%
Lessee, Operating Lease, Liability, to be Paid $14,802,000 USD -1.5%
Property, Plant and Equipment, Gross $20,126,000 USD 5.3%
Operating Lease, Liability, Current $348,000 USD -67%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,462,000 USD -13%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,153,000 USD -40%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6,029,000 USD 2%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,506,000 USD -5.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $14,715,000 USD 2.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,538,000 USD 8.6%
Operating Lease, Payments $385,000 USD -27%
Additional Paid in Capital $1,360,890,000 USD 7.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $331,000 USD 8.2%
Share-based Payment Arrangement, Expense $82,612,000 USD 36%
Interest Expense $101,167,000 USD -5.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%